Background: Herpes simplex encephalitis (HSE) after primary herpes simplex virus (HSV)-1 infection can occur in children due to inborn errors of cell-intrinsic immunity in the central nervous system. Paradoxically, symptomatic mucocutaneous HSV-1 recurrences are rare survivors of childhood HSE. T-cell-acquired immunity is thought to be involved in control of recurrent mucocutaneous HSV infection. We thus tested HSV-1-specific immunity in HSE survivors. Methods: We obtained serum and peripheral blood mononuclear cells (PBMCs) from participants a median of 13.5 years after HSE. HSV-1 and HSV-2 IgG was detected by type-specific immunoblot. PBMCs from subjects passing quality control criteria were tested using enzyme-linked immunospot assay for CD4 interferon-γ responses with an HSV-1 lysate and for CD8 responses using pooled synthetic HSV-1 peptide CD8 T-cell epitopes. Healthy adult PBMCs were used to standardize assays and as comparators. Results: All participants were HSV-1 seropositive. Most (23/24) HSE survivors had human leukocyte antigen class I types matching the human leukocyte antigen restriction of the pooled peptides. We detected HSV-specific CD8 T-cell responses in 14 of 24 (58%) HSE survivors and in 9 of 9 healthy HSV-1 seropositive adults. HSV-specific CD4 T-cell responses were present in all 5 HSE subjects tested and in 8 of 9 healthy adults. Response magnitudes were overlapping between subject groups. Conclusions: The defects in cell-intrinsic immunity leading to failure to control primary central nervous system HSV-1 infection do not preclude the acquisition of specific immunity or the control of recurrent mucocutaneous HSV infections. The rarity and lack of severe or recurrent mucocutaneous HSV infection in survivors of childhood HSE corresponds with intact adaptive T-cell immunity.
H
erpes simplex virus (HSV)-1 is a prevalent virus that typically causes herpes labialis (cold sores) and is usually acquired during childhood. In very rare postneonatal children, primary HSV-1 infection is not limited to epithelia and innervating ganglia, but spreads to cause HSV encephalitis (HSE). This condition may affect adolescents and, more rarely, young adults. 1 These patients do not display mucocutaneous lesions during HSE, and the virus does not infect other organs than the central nervous system (CNS). Recently, a series of lesions in genes involved in toll-like receptor 3 (TLR3)-and type I interferon (IFN)-mediated cell-intrinsic antiviral responses operating in the CNS have been identified in collectively about 5% of tested HSE children. 2 It is currently unknown if the remaining individuals harbor as-yet unknown genetic lesions. Regardless, childhood HSE is a devastating condition, with high mortality in the absence of treatment with acyclovir and high proportion of neurologic sequelae in acyclovir-treated survivors.
Neonatal HSE is a distinct clinical entity linked to inoculation of mucocutaneous surfaces with large amounts of HSV, typically HSV-2, with the highest risk per exposure in the setting of the absence of placental transferred antibody during primary maternal HSV-2. Cases also occur during established, recurrent genital herpes at a much lower per-exposure rate. 3 It has not been studied for germline genetic lesions. These patients can have disseminated disease caused by HSV-2 involving the CNS, visceral organs, skin and mucosae or with overlap between these 3 classic syndromes. Neonatal HSE survivors are prone to both CNS and peripheral relapses, with 40%-80% having mucocutaneous lesions by 6-8 months after primary treatment depending on receipt of suppressive antivirals. 3 In contrast, clinical CNS relapses after childhood HSE are rare (around 10%), and survivors of childhood HSE are paradoxically not prone to herpes labialis, before, during and after HSE. Acquired immunity seems not to be involved in host defense against childhood HSE, as children with the prevalent forms of severe combined immune deficiency (SCID) lacking both T-and B-cell responses are not prone to HSE. 4 However, T-cells participate in control of recurrent mucocutaneous HSV, such that antiviral prophylaxis is recommended for HSV-seropositive children with SCID 4 to prevent episodic epithelial infection. CD8 T-cells can kill HSV-infected cells or secrete antiviral cytokines, and in animals directly protect against HSV reinfection. CD4 T-cells also function in animal models and their decrease is implicated in poor HSV control during HIV coinfection. 5 HLA-restricted CD8 and CD4 T-cell traffic from blood to HSV lesions and reside as tissue resident memory (T RM ) cells in skin, mucosae and ganglia. 5, 6 Most of these findings apply to both viral types, albeit not all systems have been explored for both HSV-1 and HSV-2.
It is remarkable that after childhood HSE, clinical CNS relapses are rare, and herpes labialis happens with lower prevalence than that of the general population, and almost never in severe or recurrent forms ( 1 and Casanova et al, unpublished data). Large population-based studies have estimated that the lifetime prevalence of herpes labialis among HSV-1 seropositive adults is 50.1%, 7 and that the annual prevalence of herpes labialis among HSV-1 seropositives is 24.1%. 8 Our preliminary data suggest that herpes labialis strikes less than 10% of survivors of HSE, and typically runs a mild clinical course (Casanova et al, unpublished data 
MATERIALS AND METHODS

Specimens
Standard diagnostic criteria were used to diagnose childhood HSE. 10 The criteria included clinical signs of meningoencephalitis, lesions on cerebral computed tomography scan and/or magnetic resonance imaging and cerebrospinal fluid polymerase chain reaction positive for HSV-1 DNA in cerebrospinal fluid and/ or detectable HSV-1-specific antibodies in serum. Data were collected by review of pertinent medical records including structured interviews.
1 Anticoagulated venous blood was obtained at Université Paris Descartes-Institut National de Santé et Recherche Médicale. Protocols were approved by Institut National de Santé et Recherche Médicale (subjects) and University of Washington (controls) Institutional Review Boards. Peripheral blood mononuclear cells (PBMCs) were cryopreserved with 10% dimethylsulfoxide (DMSO) using standard methods.
Laboratory Studies
Modified published IFN-γ enzyme-linked immunospot assay (ELISPOT) methods were used.
11 Thawed PBMCs were rested overnight, viability checked (Guava; EMD Millipore, Billerica, MA) and 250,000 cells/well plated. Antigens included 0.3% DMSO, 3 pools of 37-40 known CD8 T-cell HSV-1 peptide epitopes [includ- 6 PBMCs. 12 An automated analyzer acquired images (CTL, Cleveland, OH). HSV IgG serology used type-specific Western blot. 13 HLA typing used standard molecular methods.
RESULTS
Subjects and Specimens
Patients providing specimens were either recruited from a previously described cohort 1 or seen subsequently. Patients were 3 months to 15 years of age at their initial HSE episode. Among specimens from 43 persons without known genetic lesions, 34 had adequate cell number after overnight rest for IFN-γ ELISPOT. Among these, 24 with >200 SFU/10 6 PBMCs to PHA positive control were analyzed for HSV-1 responses. For these 24 patients, the median age at HSE was 18.5 months (range: 1-156), median age at phlebotomy was 16 years (range: 5-36) and median interval between HSE and phlebotomy was 13.5 years (range: 4-33). All 22 subjects with serum available were HSV-1 IgG seropositive; 3 were also HSV-2 seropositive (Table 1) . HLA typing, available on 23 subjects, showed all but 1 was HLA matched to the CD8 peptide set at HLA A and/or B. Two of 24 (8.3%), neither of whom were in our previous cohort study, 1 had recurrent herpes labialis after HSE. Two had HSE recurrences either at age 2, 1 year after initial presentation (subject: 01353), or 14 months and 14 years after an initial presentation at 10 months (subject: 01983). Two were born to consanguineous parents. Five had moderate/severe sequelae, 5 had mild neurologic sequelae and 14 had favorable recovery. Among 9 HSV-1 seropositive adult healthy donors (median age: 43; range: 29-65), 5 had a history of oral herpetic lesions and 2 were HSV-2 seropositive.
T-cell Responses
CD8 IFN-γ responses were evaluated using pools of HSV-1 peptide epitopes in 16 subjects. For the other 8, limited PBMCs required testing 1 inclusive peptide pool (Table 1) . We observed that 14 of 24 (58%) HSE survivors had a positive response to HSV-1 peptides (>20 SFU/10 6 PBMC). This included 9 of 16 tested with 3 peptide subpools and 5 of 8 tested with a single inclusive pools. Among the 2 subjects with recurrent herpes labialis, 1 each was positive and negative for CD8 T-cell responses. IFN-γ responses were observed for 9 of 9 (100%) control HSV-1 seropositive adults. HSE survivors generally had lower magnitudes than controls, but the responses overlapped. Many HSE survivors reacted to >1 peptide pool, implying a polyepitope CD8 response. We did note some subjects such as 00240, 00378 and 01806 with absent CD8 responses to HSV-1 peptides, despite maximal PHA control responses.
Among 5 subjects with sufficient PBMC, all showed CD4 IFN-γ responses to whole HSV-1 antigen, including 1 (01806) without detectable CD8 responses. CD4 responses in adult controls were variable but present in 8 of 9 (89%), with 1 showing <20 SFU/10 6 PBMC despite brisk CD8 responses.
DISCUSSION
The observations that childhood HSE is dissociated from simultaneous infection at other sites, and that mucocutaneous lesions (orolabial herpes) are rare and mild in survivors, suggested HSE pathogenic mechanism(s) specific to CNS cells. Indeed, in vitro experiments indicated that mutations in genes of the TLR3-IFN pathway genes, such as TLR3 or UNC93B1, increased HSV-1 susceptibility intrinsically in neurons. 2 In this report, we investigated acquired immunity to HSV-1 in HSE survivors without a currently known genetic lesion, hoping to gain clues to the general lack of mucocutaneous HSV-1 infection in these persons. Overall, our data showed that CD8 T-cell responses to HSV-1 are similar in HSV-1 seropositive healthy donors and survivors of childhood HSE, including children with recurrent HSE and 1 of 2 with herpes labialis. The unknown host factors responsible for these cases of childhood HSE do not preclude the development of CD8 T-cell responses.
We observed heterogeneity among childhood HSE survivors for CD8 responses. In general, the magnitude of both CD4 and CD8 responses was lower in HSE survivors than healthy adults, but PBMC viability was also lower, such that dichotomous rather than quantitative results are most appropriate when evaluating responses in these specimens. Overall, most patients had a positive response in CD8 assays. For these individuals, while the pathogenesis of their original HSE remains obscure, innate-acquired immune cooperation to prime and maintain HSV-1-specific T-cell responses is intact. This is consistent with the finding that the known genetic disorders for childhood HSE are CNS-intrinsic, 2 and SCID is not associated with childhood HSE.
14 One subject with recurrent herpes labialis after HSE showed detectable (10 SFU/10 6 PBMC) CD8 responses below our positivity threshold. The low peptide concentrations tested for this subject may have reduced assay sensitivity. Given variability between HLA-compatible persons for peptide-specific responses, further tests are required to definitively assign any subject as CD8 T-cell nonresponders. An alternative test of CD8 responses to whole HSV-1 using dendritic cell cross presentation, overcoming HLA and T cell receptor repertoire issues, requires more blood than was available for this study. 11 We also did not have adequate PBMC to test whole virus CD4 responses in most persons, but each HSE survivor tested was positive. It cannot be excluded that some HSE survivors, despite intact B-cell responses as measured by serum IgG, have a somewhat impaired T-cell response, as suggested in this report several years after HSE. Studies to address this would similarly require additional specimens for thorough investigation. Regardless, they do not display any clinical signs of T-cell deficit, including mucocutaneous HSV-1 lesions. Most HSE survivors, including 2 persons suffering from CNS relapse, have detectable adaptive blood IFN-γ responses to HSV-1 when tested approximately a decade later. The responses were not quantitatively different from normal donors, despite the absence of mucocutaneous disease in most of HSE survivors. We are left with the unexplained clinical dichotomy of severe CNS primary yet asymptomatic mucocutaneous chronic-phase infections in most survivors of childhood HSE. The simplest hypothesis to account for this, supported so far by our mechanistic findings covering about 5% of childhood HSE, is that the abnormalities in CNS cell-intrinsic immunity to HSV-1 that underlie HSE 2 do not prevent acquired T-cell responses. The number of circulating CD8 T-cells with IFN-γ responses to HSV-1 does not appear to be a key factor differentiating HSV-1 recurrence in most childhood HSE survivors, who rarely have mucocutaneous recurrences, from healthy adults, among whom 25%-50% do have recurrences. Further research is needed to detect possible differences in T-cell abundance, effector functions, exhaustion, homing or tissue residence. While herpes labialis was studied in a structured interview for most of our patients, it is possible that additional cases would be uncovered with a serial, prospective approach. Ultimately, a prospectively followed cohort with disease phenotype and longitudinal specimen collection, host and possibly virus genotyping, and detailed neuronal cell-intrinsic and leukocyte innate and acquired immune studies will be required to explain the benign course of HSV infection after recovery. 
